NCT06529744 Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling
| NCT ID | NCT06529744 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Dementia |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2023-11-11 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2023-11-11 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To develop a model to predict disease progression in a large cohort of patients across a variety of neurodegenerative diseases, including Mild Cognitive Impairment (MCI) and dementia due to any neurodegenerative disease, including Alzheimer's Disease (AD), Lewy Body Disease (LBD), Vascular Disease (VaD) and Frontotemporal lobar degeneration (FTLD).
Eligibility Criteria
Inclusion Criteria: * Possible or probable diagnosis of MCI or early dementia * Age 30-95 * Study partner who has some weekly contact with patient. Some of the neuropsychological assessment require collateral from close contacts to assess cognition and functioning. Since neurodegenerative diseases can be associated with reduced cognition, including reduced awareness of one's own impairments, participants will be assessed for their capacity to consent at all study visits. * Must, in the opinion of the site investigator, be able to complete most study procedures. Exclusion Criteria: * Participants who are not able to complete the majority of assessments in the opinion of the PI are excluded from the study. Exclusion criteria are evaluated at the site investigator's discretion; if the site investigator believes that the participant's symptoms are due to causes other than neurodegeneration, despite the presence of an exclusionary condition, the investigator may overrule the exclusion.
Contact & Investigator
Maria C Tartaglia, M.D.
PRINCIPAL INVESTIGATOR
Toronto Western Hospital, UHN; Tanz CRND
Frequently Asked Questions
Who can join the NCT06529744 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 95 Years, studying Dementia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06529744 currently recruiting?
Yes, NCT06529744 is actively recruiting participants. Contact the research team at claudia.clementi@uhn.ca for enrollment information.
Where is the NCT06529744 trial being conducted?
This trial is being conducted at North York, Canada, Toronto, Canada, Toronto, Canada, Toronto, Canada.
Who is sponsoring the NCT06529744 clinical trial?
NCT06529744 is sponsored by University Health Network, Toronto. The principal investigator is Maria C Tartaglia, M.D. at Toronto Western Hospital, UHN; Tanz CRND. The trial plans to enroll 500 participants.